Hyposensitivity to the amnesic effects of scopolamine or amyloid β25-35 peptide in heterozygous acetylcholinesterase knockout (AChE+/-) mice

Chemico-Biological Interactions

Volumn 175, Issue 1-3, 2008, Pages 131-134

  Espallergues, Julie ^a,b,c   Galvan, Laurie ^a,b,c   Lepourry, Laurence ^c,d   Bonafos, Béatrice ^c,d   Maurice, Tangui ^a,b,c   Chatonnet, Arnaud ^c,d  

^a University of Montpellier   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIV MONTPELLIER   (France)

^d University of Montpellier   (France)

Author keywords

Acetylcholinesterase; Amyloid peptide; Forced swimming; Knockout mouse; Learning and memory; Scopolamine

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[25-35]; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; HETEROZYGOSITY; HYPERACTIVITY; KNOCKOUT MOUSE; LEARNING; LEARNING DISORDER; LOCOMOTION; MALE; MAZE TEST; MEMORY; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR;

ACETYLCHOLINESTERASE; AMNESIA; AMYLOID BETA-PROTEIN; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROZYGOTE; MAZE LEARNING; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PEPTIDES; SCOPOLAMINE;

MUS;

EID: 50649117761     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.04.001     Document Type: Article

References (10)

1. Volpicelli-Daley L.A., Duysen E.G., Lockridge O., and Levey A.I. Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Ann. Neurol. 53 (2003) 788-796
2. Mattson M.P. Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD. Neurobiol. Aging 16 (1995) 447-457
3. Cotman C.W. The β-amyloid peptide, peptide self-assembly, and the emergence of biological activities. A new principle in peptide function and the induction of neuropathology. Ann. N.Y. Acad. Sci. 814 (1997) 1-16
4. Francis P.T., Nordberg A., and Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol. Sci. 26 (2005) 104-111
5. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Niidome T., Sugimoto H., Fujii T., Okabe S., and Akaike A. Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur. J. Pharmacol. 549 (2006) 19-26
6. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., and Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51 (2006) 474-486
7. Girard E., Barbier J., Chatonnet A., Krejci E., and Molgo J. Synaptic remodeling at the skeletal neuromuscular junction of acetylcholinesterase knockout mice and its physiological relevance. Chem. Biol. Interact. 157-158 (2005) 87-96
8. Girard E., Bernard V., Minic J., Chatonnet A., Krejci E., and Molgo J. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice. Life Sci. 80 (2007) 2380-2385
9. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res. 706 (1996) 181-193
10. Fisher A. Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives. Expert Opin. Investig. Drugs 6 (1997) 1395-1411